| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/05/2012 | CA2802037A1 Metronidazole esters for treating rosacea |
| 01/05/2012 | CA2802036A1 Once-a-month method of contraception |
| 01/05/2012 | CA2801991A1 Metronidazole esters for treating rosacea |
| 01/05/2012 | CA2801977A1 Metronidazole esters for treating rosacea |
| 01/05/2012 | CA2801826A1 Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate |
| 01/05/2012 | CA2801814A1 Quinazoline compounds |
| 01/05/2012 | CA2801466A1 Use of squaramide in the prevention and/or treatment of rosacea |
| 01/05/2012 | CA2801243A1 Methods of treating restless legs syndrome |
| 01/05/2012 | CA2801241A1 Methods for treating bipolar disorder |
| 01/05/2012 | CA2800836A1 Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity |
| 01/05/2012 | CA2800301A1 N-acyl amino acid derivatives for treating skin conditions such as cellulite |
| 01/05/2012 | CA2799587A1 Compounds for the treatment of posterior segment disorders and diseases |
| 01/05/2012 | CA2798028A1 Liquid formulations of rupatadine fumarate |
| 01/05/2012 | CA2795923A1 Tapentadol for use in the treatment of irritable bowel syndrome |
| 01/04/2012 | EP2402753A1 Analysis of sulfated polysaccharides |
| 01/04/2012 | EP2402455A1 Process for producing carotenoid |
| 01/04/2012 | EP2402443A2 Therapeutic uses of inhibitors of rtp801 |
| 01/04/2012 | EP2402435A2 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
| 01/04/2012 | EP2402429A1 Equol-producing bacterium and use thereof |
| 01/04/2012 | EP2402387A1 Use of an article based on a polymeric composition |
| 01/04/2012 | EP2402362A2 Crystalline forms of smilagenin |
| 01/04/2012 | EP2402361A1 Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17-carbothioate and intermediates |
| 01/04/2012 | EP2402360A1 Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17-carbothioate and intermediates |
| 01/04/2012 | EP2402358A2 2',3'-Didehydro-3'-deoxy-4'-ethynylothymidine derivatives for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and pharmaceutically acceptable forms of drugs |
| 01/04/2012 | EP2402357A1 Analogs of 2',3'-dideoxy-3'-fluorothymidine 5'-monophosphate (FLTMP) for treatment human immunodeficiency virus (HIV), their application and pharmaceutically acceptable form of drug |
| 01/04/2012 | EP2402356A2 Modified 2',3'-dideoxynucleosides for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and the pharmaceutical agent containing these nucleosides |
| 01/04/2012 | EP2402355A1 Crystalline anhydrous forms II and III of Tulathromycin |
| 01/04/2012 | EP2402350A1 New water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins. |
| 01/04/2012 | EP2402349A1 Tricyclic pyrazolopyrimidine derivative |
| 01/04/2012 | EP2402347A1 Pharmaceutical compounds |
| 01/04/2012 | EP2402342A1 Pharmaceutical composition for treatment of 2 type dabetes |
| 01/04/2012 | EP2402341A2 Purinyl derivatives and their use as potassium channel modulators |
| 01/04/2012 | EP2402334A1 Inhibitors of E1 Activating Enzymes |
| 01/04/2012 | EP2402333A1 1,4-benzothiazepine-1-oxide derivative and pharmaceutical composition utilizing the same |
| 01/04/2012 | EP2402331A1 Inhibitors of serine proteases |
| 01/04/2012 | EP2402330A1 Pyrazolone-derivatives as PDE4 inhibitors |
| 01/04/2012 | EP2402327A1 Acetamide compounds as glucokinase activators, their process and medicinal applications |
| 01/04/2012 | EP2402326A1 Crystals of hydrochloride salts of a Phenylalanine Derivative, Production Method Thereof and Use Thereof as alpha4 integrin Inhibitors |
| 01/04/2012 | EP2402325A2 Hydroxylated and methoxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors |
| 01/04/2012 | EP2402323A2 Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| 01/04/2012 | EP2402322A1 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
| 01/04/2012 | EP2402321A2 Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof |
| 01/04/2012 | EP2402320A1 Anorectic agents |
| 01/04/2012 | EP2402319A1 DGAT Inhibitors |
| 01/04/2012 | EP2402318A1 DGAT inhibitors |
| 01/04/2012 | EP2402317A1 DGAT inhibitor |
| 01/04/2012 | EP2402316A1 Piperidine derivatives |
| 01/04/2012 | EP2402314A1 (Aza)indole derivative and use thereof for medical purposes |
| 01/04/2012 | EP2402311A1 Modafinil polymorphic form VI |
| 01/04/2012 | EP2402310A1 CCR9 inhibitors and methods of use thereof |
| 01/04/2012 | EP2402309A1 CCR9 inhibitors and methods of use thereof |
| 01/04/2012 | EP2402305A1 Loxoprofen derivative and pharmaceutical containing same |
| 01/04/2012 | EP2402300A1 Hydroxyl compounds and compositions for cholesterol management and related uses |
| 01/04/2012 | EP2402036A1 Cyclodextrin-based polymers for delivering the therapeutic agents covalently attached thereto |
| 01/04/2012 | EP2402034A1 A method for screening for a substance having an action of proliferating natural killer cells |
| 01/04/2012 | EP2402033A1 Cell adhesion inhibitor and use thereof |
| 01/04/2012 | EP2402017A1 Carbon monoxide removal agent |
| 01/04/2012 | EP2402016A1 Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor |
| 01/04/2012 | EP2402015A2 Method of producing sophorolipids by fermentation of candida bombicola |
| 01/04/2012 | EP2402014A2 Application of sophorolipids synthesized by fementation of candida bombicola |
| 01/04/2012 | EP2402013A1 Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist |
| 01/04/2012 | EP2402012A2 Liquid formulations of rupatadine fumarate |
| 01/04/2012 | EP2402011A1 Intermediates in the synthesis of S-triazolyl alpha-mercaptoacetanildes as inhibitors of HIV reverse transcriptase |
| 01/04/2012 | EP2402010A1 Solid drug for oral use |
| 01/04/2012 | EP2402009A1 Inhibitors of serine protease, particularly hepatitis c virus NS3-NS4A protease, incorporating a fused ring system |
| 01/04/2012 | EP2402008A1 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| 01/04/2012 | EP2402007A1 Coenzyme q10-containing composition for oral ingestion |
| 01/04/2012 | EP2402005A1 Sustained release formulations of nalbuphine |
| 01/04/2012 | EP2402004A2 Methods and compositions for deterring abuse of opioid containing dosage forms |
| 01/04/2012 | EP2402003A2 Diclofenac formulations and methods of use |
| 01/04/2012 | EP2402002A1 Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| 01/04/2012 | EP2401914A1 Antiseptic based on bispyridinium alkanes |
| 01/04/2012 | EP2401397A2 Protein targets in disease |
| 01/04/2012 | EP2401375A1 Improved design of small-interfering rna |
| 01/04/2012 | EP2401282A1 Method for the production of amorphous rifaximin |
| 01/04/2012 | EP2401281A1 Pyrimidopyrimidoindazole derivative |
| 01/04/2012 | EP2401280A1 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| 01/04/2012 | EP2401279A1 1, 4-disubstituted piperidines as vasopressin receptor via antagonists |
| 01/04/2012 | EP2401277A1 Salt of tetrahydrotriazolopyridine derivative and crystal thereof |
| 01/04/2012 | EP2401276A1 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| 01/04/2012 | EP2401275A1 Novel bronchodilating diazaheteroaryls |
| 01/04/2012 | EP2401274A1 Imidazo [1, 2 -a]pyridines as jnk modulators |
| 01/04/2012 | EP2401273A1 Tri-cyclic pyrazolopyridine kinase inhibitors |
| 01/04/2012 | EP2401272A2 Amorphous salt of a macrocyclic inhibitor of hcv |
| 01/04/2012 | EP2401271A1 Isoxazole / o-pyridine derivatives with ethyl and ethenyl linker as gaba a alpha5 receptor inverse agonists |
| 01/04/2012 | EP2401270A1 Pyrazole derivatives used as ccr4 receptor antagonists |
| 01/04/2012 | EP2401269A1 Indole derivatives as crth2 receptor antagonists |
| 01/04/2012 | EP2401268A1 Oxyindole derivatives with motilin receptor agonistic activity |
| 01/04/2012 | EP2401267A1 Jak kinase modulating quinazoline derivatives and methods of use thereof |
| 01/04/2012 | EP2401266A1 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, pharmaceutical and cosmetic compositions containing them |
| 01/04/2012 | EP2401264A2 Peptoid oligomers, pharmaceutical compositions and methods of using the same |
| 01/04/2012 | EP2401263A2 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same |
| 01/04/2012 | EP2401262A1 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/04/2012 | EP2401261A1 N-phenylacetamide derivatives, which inhibit the enzyme soat-1 and pharmaceutical and cosmetic compositions containing them |
| 01/04/2012 | EP2401260A1 Dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/04/2012 | EP2401259A1 Novel n-phenylacetamide derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/04/2012 | EP2401257A1 Enzyme inhibitors |
| 01/04/2012 | EP2401256A1 Compounds as bradykinin b1 antagonists |
| 01/04/2012 | EP2401255A1 Catecholamine derivatives and prodrugs thereof |
| 01/04/2012 | EP2400988A1 Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin |